Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region
| Autor: | Khalid Shirazy, Abdul-Ghani Kibbi, Issam R Hamadah, Samer Ghosn, Anwar Al Hammadi, Afaf Al-Sheikh, Paolo Gisondi, Alfred Ammoury |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Pathology Attitude of Health Personnel Best practice Cost-Benefit Analysis Clinical Decision-Making Alternative medicine Dermatology Disease Biologics treatment 030207 dermatology & venereal diseases 03 medical and health sciences Psoriatic arthritis Middle East 0302 clinical medicine Psoriasis Medicine Humans Clinical significance guidelines Practice Patterns Physicians' Intensive care medicine 030203 arthritis & rheumatology Biological Products business.industry co-morbidities screening Incidence (epidemiology) Arthritis Psoriatic Disease Management medicine.disease Health Care Surveys Africa Dermatologic Agents business |
| Zdroj: | The Journal of dermatological treatment. 28(2) |
| ISSN: | 1471-1753 |
| Popis: | The incidence of psoriasis in Africa and the Middle East (AfME) is high as in other regions and represents a significant problem for both dermatologists and patients. Psoriasis co-morbidities such as obesity, cardiovascular disease and psoriatic arthritis (PsA) are also particularly common in these regions and may be under-recognized and under-treated. Despite this, regional guidelines to aid physicians on the appropriate use of biologic agents in their clinical practice are limited. A group of expert dermatologists from across the AfME region were surveyed to help establish best practice across the region, alongside supporting data from the literature. Although biologics have significantly improved patient outcomes since their introduction, the results of this survey identified several unmet needs, including the lack of consensus regarding their use in clinical practice. Discrepancy also exists among AfME physicians concerning the clinical relevance of immunogenicity to biologics, despite increasing data across inflammatory diseases. Significant treatment and management of challenges for psoriasis patients remain, and a move towards individualized, tailored care may help to address these issues. The development of specific local guidelines for the treatment of both psoriasis and PsA could also be a step towards understanding the distinct patient profiles in these regions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|